Back

Comparison of transcoronary ablation of septal hypertrophy (TASH) and Mavacamten treatment in patients with obstructive hypertrophic cardiomyopathy: a single-center study

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Hypertrophic obstructive cardiomyopathy: treatment, monitoring, and outcomes Hypertrophic Cardiomyopathy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Jan Koelemen

University Hospital Heidelberg, Heidelberg (Germany)

6 More presentations in this session

Presentation thumbnail
Artificial intelligence-enabled electrocardiography to predict left ventricular ejection fraction decline in patients with obstructive hypertrophic cardiomyopathy receiving mavacamten
Doctor J. Choi (Seongnam, KR)
Abstract
Presentation thumbnail
No increase in arrhythmia burden following aficamten treatment in obstructive hypertrophic cardiomyopathy: extended ambulatory electrocardiogram analysis from FOREST-HCM
Doctor E. Rowin (Burlington, US)
Abstract
Presentation thumbnail
Evaluation of the hypothetical risk of sudden cardiac death in obstructive HCM patients treated with mavacamten using the HCM Risk-SCD score
Doctor R. Esculudes Dos Santos Ferrao Gomes (Lisboa, PT)
Abstract
Presentation thumbnail
Real-world individual patient-level analysis for mavacamten in obstructive hypertrophic cardiomyopathy: multi-domain response, safety and cyp2c19 genotype effects
Doctor P. Zwetsloot (Rotterdam, NL)
Abstract
Presentation thumbnail
The effect of mavacamten therapy on the risk of sudden cardiac death among patients with hypertrophic obstructive cardiomyopathy
Doctor F. Banfi-Bacsardi (Budapest, HU)
Abstract

Access the full session

Session thumbnail
Hypertrophic obstructive cardiomyopathy: treatment, monitoring, and outcomes

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources